Danaher reported Q4 revenue of $6.84 billion, up about 5% year‑over‑year and topping analyst estimates, powered by continued strength in bioprocessing and life‑sciences consumables. The biotechnology segment grew roughly 9% in the quarter to $2.03 billion, while diagnostics and life‑sciences equipment also posted gains. Danaher highlighted a recent FDA 510(k) clearance for a Cepheid multiplex panel as a diagnostic win. Management said core growth was supported by high demand for consumables and mid‑single‑digit equipment sales recovery. The results signal durable end‑market demand across tools and diagnostics that underpin R&D and clinical operations, supporting investment in recurring revenue hardware and consumables.